Julien Kirchgesner

Oct 7, 2024 | onlinelibrary.wiley.com | Nathan Grellier |Saint-Antoine Paris France |Julien Kirchgesner

We fully agree with the conclusions presented in the editorial by Drs. Pillay and Christensen [1], on our work (the ERIC study) [2], which emphasised the importance of early surgical intervention in certain cases of Crohn's disease (CD). We also believe that surgery should always be discussed in an integrated way for complicated CD but also for pure inflammatory ileal CD given the findings of the LIR!C trial [3, 4].

Sep 5, 2024 | onlinelibrary.wiley.com | Nathan Grellier |CRSA Sorbonne Université |Julien Kirchgesner |Mathieu Uzzan

1 INTRODUCTION Crohn's disease (CD) is a lifelong inflammatory disease affecting an increasing number of patients worldwide.1, 2 All segments of the gastrointestinal tract can be affected. The disease is limited to the terminal ileum in about one-third of the patients at diagnosis with a non-stricturing and non-penetrating disease for most of them.3 However, about 20% of patients have a complicated disease at diagnosis that may lead to early surgery.

Sep 2, 2024 | onlinelibrary.wiley.com | Julien Kirchgesner |Hôpital Saint-Antoine |Shirley Wang |Sebastian Schneeweiss

Corresponding Author Julien Kirchgesner Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA AP-HP, Hôpital Saint-Antoine, Department of Gastroenterology, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France Correspondence: Julien Kirchgesner ([email protected]) Sebastian Schneeweiss ([email protected]) Search for...

Jul 20, 2023 | onlinelibrary.wiley.com | Louis Calméjane |David Laharie |Julien Kirchgesner |Mathieu Uzzan

Infliximab or ciclosporin: Considerations for the choice of treatment As seen previously, infliximab and ciclosporin have both proved effective for the management of ASUC. The selection of second-line therapies can be influenced by clinicians' habits, patients' features, safety, or efficacy concerns. While CNIs can induce a swift response, infliximab is usually favored due to fewer monitoring and better safety profile.

Jul 15, 2023 | onlinelibrary.wiley.com | Julien Kirchgesner |Hôpital Saint-Antoine |Laurent Beaugerie

LINKED CONTENT This article is linked to Wolf et al papers. To view these articles, visit https://doi.org/10.1111/apt.17495 and https://doi.org/10.1111/apt.17565 We thank Dr. Velayos for his comments about our article,1, 2 summarising previous literature on post-inflammation polyps (PIPs) in inflammatory bowel disease (IBD) and highlighting the clinical implication of our findings.